Trial Profile
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Cetuximab sarotalocan (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker; Registrational
- Sponsors Rakuten Medical
- 01 Dec 2021 Results assessing the safety, pharmacokinetics and efficacy of RM-1929 photoimmunotherapy in patients with heavily pretreated recurrent head and neck squamous cell carcinoma, published in the Head and Neck.
- 27 Oct 2021 Results published in the Media Release
- 27 Oct 2021 According to a Rakuten Medical media release, Data from this study was published in Head and Neck.